Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2676
Peer-review started: September 9, 2014
First decision: September 28, 2014
Revised: July 29, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 18, 2015
Hepatitis C virus (HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease. Management of chronic HCV is aimed at preventing cirrhosis, reducing the risk of HCC, and treating extra hepatic complications. New treatments for chronic HCV has been devoted based on direct-acting antivirals, as pegylated interferon (peginterferon) is responsible for many side effects and limits treatment access. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens.
Core tip: Peginterferon is responsible for many side effects. Direct-acting antiviral drugs represent a breakthrough in hepatitis C virus (HCV) therapy. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens. The next few years are expected to introduce more new drugs in the market of HCV therapy with complete elimination of pegylated interferon and ribavirin combination therapy.